<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416494</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00008646</org_study_id>
    <secondary_id>DUMC-4951-05-7R2</secondary_id>
    <secondary_id>GENENTECH-DUMC-4951-05-7R2</secondary_id>
    <secondary_id>SANOFI-DUMC-4951-05-7R2</secondary_id>
    <secondary_id>ROCHE-DUMC-4951-05-7R2</secondary_id>
    <secondary_id>CDR0000449971</secondary_id>
    <nct_id>NCT00416494</nct_id>
  </id_info>
  <brief_title>Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer</brief_title>
  <official_title>Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herbert Hurwitz, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine, and oxaliplatin, work in
      different ways to stop the growth of tumor cells, either by killing the cells or by stopping
      them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
      different ways. Some find tumor cells and kill them or carry tumor-killing substances to
      them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may
      also stop the growth of tumor cells by blocking blood flow to the tumor. Giving capecitabine
      and oxaliplatin together with bevacizumab may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving oxaliplatin and capecitabine
      together with bevacizumab works in treating patients with metastatic or recurrent colorectal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the response rate in patients with previously untreated metastatic colorectal
           cancer treated with capecitabine, oxaliplatin, and bevacizumab.

      Secondary

        -  Assess time to progression (TTP), disease-free survival (DFS), and overall survival (OS)
           in patients treated with this regimen.

        -  Assess the safety and tolerability of bevacizumab, oxaliplatin, and capecitabine in
           patients with previously untreated metastatic colorectal cancer.

      Exploratory

        -  Evaluate the effect of this regimen on the biomarkers of angiogenesis.

        -  Assess the effect of this regimen on wound angiogenesis.

      OUTLINE: Patients receive oral capecitabine twice daily on days 1-5 and 8-12, oxaliplatin IV
      over 2 hours on day 1, and bevacizumab IV over 1-1½ hours on day 1. Courses repeat every 14
      days in the absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (Percentage of Participants With Partial or Complete Response)</measure>
    <time_frame>After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.</time_frame>
    <description>Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.
Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
The definitions were:
Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From time of treatment until documented progression, assesed up to 60 months.</time_frame>
    <description>Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.</time_frame>
    <description>Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From time of treatment until death from any cause, assesed up to 60 months.</time_frame>
    <description>Average months of survival of participants after receiving study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>After all participants went off study drug regimine.</time_frame>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect on Angiogenesis Biomarkers</measure>
    <time_frame>After study completion</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect on Wound Angiogenesis</measure>
    <time_frame>After study completion</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Initial Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Second cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>10 mg/kg intravenously over 30-90 minutes on day 1</description>
    <arm_group_label>Initial Cohort</arm_group_label>
    <arm_group_label>Second cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>85 mg/m2 intravenously over 2 hours on day 1.</description>
    <arm_group_label>Initial Cohort</arm_group_label>
    <arm_group_label>Second cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort</description>
    <arm_group_label>Initial Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
    <arm_group_label>Second cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically documented adenocarcinoma of the colon or rectum

               -  Metastatic or recurrent disease not amenable to potentially curative treatment
                  (e.g., inoperable metastatic disease)

          -  No leptomeningeal or brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Absolute neutrophil count ≥ 2,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  AST/ALT &lt; 2.5 times upper limit of normal (ULN) (5 times ULN if known liver
             metastases)

          -  Bilirubin &lt; 1.5 times ULN

          -  Creatinine clearance &gt; 50 mL/min

          -  No unstable or poorly controlled hypertension (&gt; 150/100 mm Hg)

               -  Patients who have recently started or adjusted antihypertensive medications are
                  eligible provided blood pressure is &lt; 140/90 mm Hg on any new regimen for at
                  least 3 different observations over 14 days

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during study and for at least 3-4
             months after study completion

          -  No arterial or venous thrombosis (including cerebrovascular accident) within the last
             3 months

          -  No known, existing, uncontrolled coagulopathy

          -  No clinically significant cardiac disease

          -  No congestive heart failure

          -  No symptomatic coronary artery disease

          -  No cardiac arrhythmias not well controlled with medication

          -  No myocardial infarction within the last 12 months

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to oxaliplatin, capecitabine, or bevacizumab

          -  No history of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that might affect the
             interpretation of the results of the study or render the patient at high risk from
             treatment complications

        PRIOR CONCURRENT THERAPY:

          -  At least 4 weeks since prior sorivudine or brivudine

          -  At least 6 months since prior adjuvant treatment with fluorouracil and leucovorin
             calcium or a fluorouracil and leucovorin calcium-based regimen

          -  No major surgery within 4 weeks without complete recovery

          -  No prior chemotherapy for metastatic/recurrent disease

          -  No cancer immunotherapy or other biologic therapy while on therapy

          -  No radiotherapy while on study

          -  No hormonal therapy for cancer while on study

          -  No full-dose warfarin (INR of &gt; 1.5), heparin (&gt; 10,000 units/day), or thrombolytic
             agents

          -  Allopurinol and cimetidine should be discontinued prior to starting on this regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert I. Hurwitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Cancer Institute</affiliation>
  </overall_official>
  <results_reference>
    <citation>Hurwitz H, Fernando N, Yu D, et al.: A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer. [Abstract] Ann Oncol 16 (Suppl 2): A-55P, ii285, 2005.</citation>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <results_first_submitted>February 12, 2013</results_first_submitted>
  <results_first_submitted_qc>February 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2013</results_first_posted>
  <last_update_submitted>August 25, 2014</last_update_submitted>
  <last_update_submitted_qc>August 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Herbert Hurwitz, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between September 2003 and July 2005 in the Duke Cancer Center and Duke Oncology Network sites.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Initial Cohort</title>
          <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
        </group>
        <group group_id="P2">
          <title>Second Cohort</title>
          <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Cohort</title>
          <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
        </group>
        <group group_id="B2">
          <title>Second Cohort</title>
          <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="13.3"/>
                    <measurement group_id="B2" value="55.3" spread="12.6"/>
                    <measurement group_id="B3" value="55" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (Percentage of Participants With Partial or Complete Response)</title>
        <description>Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.
Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
The definitions were:
Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions</description>
        <time_frame>After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.</time_frame>
        <population>All subjects who had restaging scans were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
          </group>
          <group group_id="O2">
            <title>Second Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Percentage of Participants With Partial or Complete Response)</title>
          <description>Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.
Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
The definitions were:
Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions</description>
          <population>All subjects who had restaging scans were included in the analysis.</population>
          <units>percentage of participants with response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="38" upper_limit="84"/>
                    <measurement group_id="O2" value="42" lower_limit="25" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>From time of treatment until documented progression, assesed up to 60 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
          </group>
          <group group_id="O2">
            <title>Second Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="5.7" lower_limit="5.7" upper_limit="19.5"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.9" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Free Survival</title>
        <description>Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
        <time_frame>From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
          </group>
          <group group_id="O2">
            <title>Second Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Free Survival</title>
          <description>Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.
Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="5.7" upper_limit="19.5"/>
                    <measurement group_id="O2" value="10.4" lower_limit="6.9" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Average months of survival of participants after receiving study drug.</description>
        <time_frame>From time of treatment until death from any cause, assesed up to 60 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
          </group>
          <group group_id="O2">
            <title>Second Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Average months of survival of participants after receiving study drug.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6" lower_limit="13.3" upper_limit="30.2"/>
                    <measurement group_id="O2" value="24.8" lower_limit="12.9" upper_limit="39.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability</title>
        <description>Number of participants with adverse events</description>
        <time_frame>After all participants went off study drug regimine.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Initial Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
          </group>
          <group group_id="O2">
            <title>Second Cohort</title>
            <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability</title>
          <description>Number of participants with adverse events</description>
          <units>participants with adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect on Angiogenesis Biomarkers</title>
        <time_frame>After study completion</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect on Wound Angiogenesis</title>
        <time_frame>After study completion</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Initial Cohort</title>
          <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1</description>
        </group>
        <group group_id="E2">
          <title>Second Cohort</title>
          <description>oxaliplatin : 85 mg/m2 intravenously over 2 hours on day 1.
bevacizumab : 10 mg/kg intravenously over 30-90 minutes on day 1
Capecitabine : Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Acute Calculus Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Wound Dehisence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Cramping</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Flatuance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="19"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="19"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="19"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot syndrome</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="19"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="19"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brant Hamel</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-68-1861</phone>
      <email>brant.hamel@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

